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ABSTRACT
Aims: The purpose of this study was to compare the performance of three automated immunoassays for the 
detection of IgM and IgG Toxoplasma gondii antibodies using sera of pregnant women living in Colombia, a Latin 
American country with a high seroprevalence. Methods: A total of 905 sera were tested for IgM antibodies and 914 
for IgG antibodies with AxSYM, VIDAS and VIDIA immunoassays. Discrepancies were resolved by using the dye 
test for IgG antibodies, and the ISAGA test for IgM. Results: The overall agreement between AxSYM, VIDAS and 
VIDIA assays was excellent for detection of IgG and IgM antibodies, and discrepancies were relatively rare (3.6% and 
5.5% of sera for IgG and IgM antibodies, respectively). The performance of the three immunoassays was similar for 
the detection of IgG antibodies with high sensitivity (100.00% for VIDIA, 99.59% for VIDAS, 99.38% for AxSYM) 
and specificity (99.04% for VIDIA, 98.82% for AxSYM, 98.57% for VIDAS). The specificity for IgM antibodies 
was excellent for the three immunassays (99.88% for VIDIA, 99.76% for AxSYM and VIDAS). The sensitivity of 
the detection of IgM antibodies was higher with VIDIA (95.12%) than with VIDAS (76.74%) and AxSYM (61.90%) 
assays. The correlation between IgG titers was limited between AxSYM and VIDAS assays and between AxSYM 
and VIDIA assays, but was excellent between VIDIA and VIDAS assays. Conclusions: Our study performed with 
Latin American sera confirmed the excellent specificity of AxSYM, VIDAS and VIDIA assays for the detection of 
IgG and IgM antibodies already reported in other countries. The sensitivity of the detection of IgG antibodies was 
slightly higher with VIDIA than with VIDAS and AxSYM assays. The sensitivity of the detection of IgM antibodies 
was higher with VIDIA than with VIDAS and AxSYM assays.
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TESTS; ANTIBODY AVIDITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; LATIN AMERICA; FEMALE; PREGNANT 
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INTRODUCTION
Toxoplasmosis  is  caused  by  the  unicellular 
protozoan  parasite  Toxoplasma  gondii ( T.  gondii). 
In  immunocompetent  subjects,  primary  infection 
is  usually  asymptomatic  or  associated  with  self-
limited  symptoms  such  as  fever,  malaise,  and 
cervical lymphadenopathy. Infection acquired during 
pregnancy is frequently associated with transmission 
of T. gondii to the fetus, resulting in congenital disease. 
In  immunocompromised  patients,  reactivation  of 
latent  infection  can  cause  life-threatening  com- 
plications.1,2
Infection  with  the  parasite  is  widespread   
throughout the world, but the seroprevalence varies 
considerably  between  countries  (from  less  than 28  Sci Med. 2010;20(1):27-34
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10%  to  more  than  90%)  and  population  groups. 
Toxoplasmosis is more prevalent in some regions of 
Europe, in Latin America, and sub-Saharan Africa, 
than  in Asia,  North America,  and  Oceania.3-5 The 
impact of toxoplasmosis on public health is especially 
high in Latin America. Severe clinical forms with 
visceral localization, mainly pulmonary involvement, 
have  been  described  after  a  primary  infection  in 
immunocompetent  subjects  in  French  Guiana.6,7  A 
high  prevalence  of  ocular  toxoplasmosis  has  also 
been reported in Brazil.8,9 T. gondii strains isolated 
from these subjects exhibited an atypical genotype, 
highly divergent from European and North American   
lineages.6,10
The diagnosis of recently acquired toxoplasmosis 
is  usually  based  on  the  detection  of  specific 
immunoglobulin (Ig) M antibodies, in conjunction 
with seroconversion or a significant increase in specific 
IgG antibodies. Methods for the detection of anti- 
T. gondii antibodies include the Sabin-Feldman dye 
test,  enzyme  immunoassay  (EIA),  immunosorbent 
agglutination assay (ISAGA), IgA and IgE antibody 
tests, the differential agglutination test, IgG avidity 
test, enzyme-linked immunofiltration assay (ELIFA) 
and  immunoblotting  (IB).1,11,12  Immunoassays  are 
among the easiest tests to perform, and automated 
systems, well adapted to large-scale screening, have 
been developed.
The purpose of this study was to compare the 
performance of different automated immunoassays, 
AxSYM® TOXO IgG and IgM (Abbott Laboratories, 
Chicago, Ill, USA), VIDAS® TOXO IgG and IgM 
(bioMérieux, Marcy l’Etoile, France) and VIDIA® 
TOXO  IgG  and  IgM  (bioMérieux)  using  sera 
collected  from  pregnant  women  living  in  a  Latin 
American country with a high seroprevalence of toxo- 
plamosis.
METHODS
Samples and patients
This  multicenter  study  was  performed  from 
October 2008 to May 2009 on frozen serum samples 
(n=920) provided by the Fundacion Valle del Lili, 
Cali,  Colombia  and  collected  during  a  previous 
epidemiological study led by the Palo Alto Medical 
Foundation  Toxoplasmosis  Serology  Laboratory, 
Stanford University School of Medicine and Fundacion 
Valle del Lili.5 The eligible population was pregnant 
women whose serum had been obtained from clinical 
blood samples already drawn for routine prenatal care 
in the ambulatory setting or for obstetric-related care 
in hospitalized patients.
Ethics
Ethics  approvals  were  obtained  for  the  epi- 
demiological  study,  from  the  institutional  review 
boards in the healthcare institutions in Cali, as well 
as in the Stanford University and Palo Alto Medical 
Foundation Research Institute. Informed consent was 
obtained from all patients referred for the Cali study. 
To preserve patient anonymity, a code was attributed 
by the evaluators to each sample tested. Investigators 
outside Fundacion Valle del Lili only had access to these 
codes and did not have access to patients’ names. 
Assays
All sera had already been tested for IgG and IgM 
T. gondii antibodies at the Fundacion Valle del Lili 
as part of the Cali study mentioned above, using the 
routine laboratory technique, VIDAS® (bioMérieux, 
Marcy l’Etoile, France) and then stored at -20°C. 
In addition, all IgG-positive/IgM-positive sera were 
tested using the VIDAS TOXO IgG Avidity assay. For 
the current study, aliquots of sera were thawed and 
clarified by centrifugation at 2000 g for 10 minutes, 
prior to testing at the Laboratoires Réunis, Junglinster, 
Luxembourg using the  VIDIA® Toxo IgG and IgM 
(bioMérieux, Marcy l’Etoile, France) and the AxSYM 
Toxo IgG and IgM (Abbott Laboratories, Chicago, 
Ill, USA) immunoassays between October 2008 and 
January 2009. Analysis was performed according to 
manufacturers’  recommendations.  Any  discrepant 
results  were  resolved  using  the  dye  test  for  IgG 
and  ISAGA  for  IgM  (Toxo-ISAGA®;  bioMérieux, 
Marcy  l’Etoile,  France),  performed  as  previously 
described13,14 at the Institut de Puériculture de Paris 
(Paris, France). 
The AxSYM, VIDAS and VIDIA systems have 
been described elsewhere.15-19 The AxSYM system   
is based on microparticle enzyme immunoassay (MEIA) 
technology with a final fluorescence detection.15,16 The 
AxSYM Toxo IgG and IgM assays use microparticles 
coated with cell-cultured T. gondii antigen (RH strain) 
as the solid phase. Bound anti-Toxoplasma IgG or IgM 
are detected with alkaline phosphatase-labeled anti-
human IgG or IgM conjugate and 4-methylumbelliferyl 
phosphate is used as a substrate. 
The VIDAS system combines a two-step enzyme 
immunoassay  for  IgG  and  an  immunocapture 
method for IgM with a final fluorescence detection   
(ELFA).17,18 The VIDAS TOXO  IgG  assay  uses  a 
solid-phase  receptacle  coated  with  membrane  and 
cytoplasmic T. gondii antigen (RH Sabin strain grown 
in mice). The conjugate uses alkaline phosphatase-
labeled mouse monoclonal anti-human IgG antibody   Sci Med. 2010;20(1):27-34  29
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and 4-methylumbelliferyl phosphate as a substrate. The 
VIDAS TOXO IgM assay uses a solid-phase receptacle 
coated with polyclonal anti-human IgM antibody (goat). 
The conjugate contains an immune complex of T. gondii 
antigen  and  alkaline  phosphatase-labeled  anti-P30 
mouse monoclonal antibody and 4-methylumbelliferyl 
phosphate is used as a substrate.
The VIDIA system combines a two-step immu- 
noassay  for  IgG  and  immunocapture  method  for 
IgM  with  paramagnetic  microparticles  and  a  final 
chemiluminescence detection.19 For VIDIA TOXO 
IgG, specific anti-T. gondii IgG are captured by the 
immunopurified cell-cultured tachyzoite antigen (RH 
Sabin strain) present on the magnetic particles, and 
then  detected  by  an  alkaline  phosphatase-labelled 
monoclonal  anti-human  IgG  antibody.  For VIDIA 
TOXO IgM, the anti-T. gondii IgM in the sample are 
captured by the monoclonal anti-human IgM antibody 
present on the magnetic particles. Bound anti-T. gondii 
IgM are detected by the immune complex of T. gondii 
antigen (RH Sabin strain grown in mice) and alkaline 
phosphatase-labeled  anti-P30  mouse  monoclonal 
antibody. During the final detection step, the substrate 
(4-methylumbelliferyl  phosphate)  is  transformed 
into a luminescent product by the conjugate alkaline 
phosphatase. 
Data analysis
Only sera tested using all three techniques were 
analyzed. A  concordance  analysis  was  performed 
between AxSYM and the other two techniques, and 
discrepant results were resolved for each case using 
the dye test and ISAGA technique. After resolution 
of discrepant results and non-inclusion of equivocal 
results, the sensitivity and specificity of each assay 
were determined by expressing the results obtained as 
a ratio of samples with appropriately assigned positive 
or negative status, respectively.
The  correlation  analysis  was  performed  on   
all  samples  with  an  antibody  titer  >0  IU/mL  and   
<300 IU/mL. A Passing-Bablok plot was used to analyze 
the agreement between the different techniques using 
Analyse-It® method validation software (Analyse-it 
Software, Ltd., Leeds, United Kingdom).20
RESULTS
Comparison between AxSYM, VIDAS and 
VIDIA immunoassays
Of  the  920  sera,  905  were  tested  for  IgM  T.  
gondii antibodies and 914 for IgG T. gondii anti- 
bodies using AxSYM, VIDAS and VIDIA immunoassays 
(Table 1).A total of 476 sera (52.1%) were positive for 
IgG antibodies, and 22 sera (2.4%) were positive for 
IgM antibodies with the three immunoassays. A total 
of 402 sera (44.0%) were negative for IgG antibodies, 
and 831 sera (91.8%) were negative for IgM antibodies 
with  the  three  immunoassays.  Discrepancies  were 
observed in 33 sera (3.6%) for IgG antibodies and 
50 sera (5.5%) for IgM antibodies. These discrepant 
sera were assessed for IgG antibodies by using the 
dye test and for IgM antibodies by using the ISAGA 
test. Using the dye test, nine sera were positive and 24 
negative for IgG antibodies. Using the ISAGA test, 28 
sera were positive, three equivocal, and 19 negative 
for IgM antibodies. Combining the concordant results 
of the three methods and the results of the reference 
tests for discrepant sera, 485 sera (476+9) (53.1%) 
were considered as true positive for IgG antibodies, 
and 50 sera (22+28) (5.5%) as true positive for IgM 
antibodies.
Comparison between AxSYM and  
VIDAS assays
The  agreement  between  AxSYM  and  VIDAS 
assays was 99.6% for positive and 98.8% for negative 
IgG  results  (Table  2).  For  IgM,  agreement  was 
81.5% for positive and 98.9% for negative results 
(Table 3). Major discrepancies (positive result with 
one  test,  and  negative  result  with  the  other  test) 
were observed for seven IgG results and for 14 IgM 
results. Using the dye test, results of the AxSYM 
assay were confirmed for three sera and those of 
VIDAS for four sera. Using the ISAGA test, results 
of the AxSYM assay were confirmed for three sera 
and results of VIDAS for nine sera, two sera being   
equivocal.
Comparison between AxSYM and  
VIDIA assays
The  agreement  between  AxSYM  and  VIDIA 
assays was 99.6% for positive and 99.0% for negative 
IgG results (Table 2). For IgM, agreement was 92.9% 
for positive and 98.7% for negative results (Table 3). 
Major  discrepancies  were  observed  for  six  IgG 
results, and for 13 IgM results. Using the dye test, 
results of the AxSYM assay were confirmed for three 
sera and those of VIDIA for three sera as well. Using 
the ISAGA test, results of the AxSYM assay were 
confirmed for one serum, and results of the VIDIA   
for 12 sera.30  Sci Med. 2010;20(1):27-34
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Table 2. Comparison of AxSYM, VIDAS and VIDIA assays for T. gondii specific IgG antibody detection
Assay Result Titer (IU/mL)
AxSYM IgG
Positive
(≥3)
Equivocal
(2-3)
Negative 
(<2) Total
VIDAS IgG Positive ≥8 480 3 5* 488
Equivocal 4-8 1 4 4 9
Negative <4 2† 3 412 417
Total 483 10 421 914
Agreement 99.6% 98.8%
VIDIA IgG Positive ≥5 477 3 4‡ 484
Equivocal 3-5 4 4 9 17
Negative <3 2§ 3 408 413
Total 483 10 421 914
Agreement 99.6% 99.0%
* 3 negative sera and 2 positive sera with the dye test;  †  2  negative sera with the dye test;  ‡ 3 negative sera and 1 positive serum with the dye test; 
§  2 negative sera with the dye test
Table 3. Comparison of AxSYM, VIDAS and VIDIA assays for T. gondii specific IgM antibody detection
Assay Result Index
AxSYM IgM
Positive 
(≥0.800)
Equivocal  
(0.600-0.799)
Negative  
(<0.600) Total
VIDAS IgM Positive ≥0.65 22 6 9* 37
Equivocal 0.55-0.65 2 2 6 10
Negative <0.55 5† 11 842 858
Total 29 19 857 905
Agreement 81.5% 98.9%
VIDIA IgM Positive ≥1.00 26 4 11‡ 41
Equivocal 0.68-1.00 1 7 13 21
Negative <0.68 2§ 8 833 843
Total 29 19 857 905
Agreement 92.9% 98.7%
* 1 negative serum, 7 positive sera and 1 equivocal serum with the ISAGA test;  † 2 negative sera, 2 positive sera and 1 equivocal serum with the 
ISAGA test;  ‡ 1 negative serum and 10 positive sera with the ISAGA test;  § 2 negative sera with the ISAGA test 
Table 1. Agreement and discrepancy between AxSYM, VIDAS and VIDIA immunoassays for the detection of T. gondii   
IgG and IgM antibodies
T. gondii 
antibody
Agreement between three assays Discrepancies 
between assays
Resolution of discrepancies*
Positive Equivocal Negative Positive Equivocal Negative
IgG 476 3 402 33 9 0 24
IgM 22 2 831 50 28 3 19
* Discrepancies were resolved by using the dye test for IgG and ISAGA test for IgM.
Sensitivity and specificity of AxSYM, VIDAS 
and VIDIA assays
IgM antibodies
After  resolution  of  discrepant  results,  the 
VIDIA  assay  presented  the  highest  sensitivity 
(95.12%),  followed  by  VIDAS  (76.74%)  and 
AxSYM  (61.90%)  assays.  The  specificity  was 
high  for  the  three  immunoassays,  i.e.  99.88%  for 
VIDIA,  99.76%  for  both  AxSYM  and  VIDAS 
(Table 4).
IgG antibodies
After resolution of discrepant results, the sensitivity 
was high for the three immunoassays, i.e. 100.00% 
for  VIDIA,  99.59%  for  VIDAS,  and  99.38%  for 
AxSYM. The specificity was also high for the three 
immunoassays, i.e. 99.04% for VIDIA, 98.82% for 
AxSYM and 98.57% for VIDAS (Table 4).  Sci Med. 2010;20(1):27-34  31
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Assay
Sensitivity* Specificity†
% [95% CI] % [95% CI]
AxSYM IgG 99.38% [98.15%; 99.79%] 98.82% [97.22%; 99.50%]
VIDAS IgG 99.59% [98.47%; 99.89%] 98.57% [96.88%; 99.36%]
VIDIA IgG 100.00% [99.17%; 100.00%] 99.04% [97.52%; 99,63%]
AxSYM IgM 61.90% [46.51%; 75.23%] 99.76% [99.12%; 99.94%]
VIDAS IgM 76.74% [61.94%; 87.00%] 99.76% [99.13%; 99.94%]
VIDIA IgM 95.12% [83.54%; 98.68%] 99.88% [99.31%; 99.98%]
* Sensitivity = true positive/(true positive + false negative)
† Specificity = true negative/(true negative + false positive)
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Table 4. Resolved sensitivities, specificities for AxSYM, VIDAS and VIDIA immunoassays 
for T. gondii specific antibody detection
Comparison between IgG antibody titers 
obtained with AxSYM, VIDAS and VIDIA
AxSYM versus VIDAS
The  relationship  between  the  titers  measured 
with the VIDAS and AxSYM assays was not linear. 
However, by performing Passing and Bablok linear 
regression, it was possible to estimate an antibody titer 
ratio which was approximately 3.5 times higher with 
the VIDAS assay than with AxSYM (Figure 1a).
AxSYM versus VIDIA 
The relationship between the titers measured with 
the VIDIA and AxSYM assays was not linear. However, 
by performing Passing and Bablok linear regression, it 
was possible to estimate an antibody titer ratio which 
was approximately 2.8 times higher with the VIDIA 
assay than with AxSYM (Figure 1b).
VIDAS versus VIDIA
The  relationship  between  the  titers  measured 
with the VIDAS and VIDIA assays was not linear. 
However, by performing Passing and Bablok linear 
regression, it was possible to estimate an antibody titer 
ratio which was approximately 1.1 times higher with 
the VIDAS assay than with VIDIA, showing that IgG 
antibody titers were very close between the two assays 
(Figure 1c).
Figure 1c. Scatter plot of IgG titers measured with VIDAS and 
VIDIA assays
Figure 1a. Scatter plot of IgG titers measured with VIDAS and 
AxSYM assays.
Figure 1b. Scatter plot of IgG titers measured with VIDIA and 
AxSYM assays.32  Sci Med. 2010;20(1):27-34
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DISCUSSION
The objective of this study was to evaluate three 
commercially  available  automated  toxoplasmosis 
immunoassays using sera collected in a Latin American 
country with a high T. gondii seroprevalence. Overall, 
53.1% of the sera tested were considered true positive 
for  IgG  T.  gondii  antibodies,  indicating  a  high 
seroprevalence in pregnant women. These results are 
consistent with the reported seroprevalence of 45.8% 
in this population.5
Most  studies  comparing  different  automated 
immunoassays have been conducted in European or 
North American countries. In these regions, T. gondii 
has a low genetic diversity, and most strains belong to 
three main clonal and closely related lineages, namely 
types I, II and III. Several studies suggest that “exotic” 
or  “atypical”  strains  circulate  in  South  America, 
Asia, and Africa. These strains are characterized by 
frequent  genetic  exchange  generating  a  variety  of 
recombinants, and a higher genetic diversity, especially 
in the Amazonian area. In immunocompetent subjects, 
atypical genotypes have been associated with severe 
clinical signs and multi-organ failure in French Guiana, 
and a higher occurrence of ocular toxoplamosis in 
Brazil.6,7,9,10,21,22
The overall agreement between AxSYM, VIDAS 
and VIDIA assays was excellent for detection of specific 
IgG  and  IgM  antibodies,  and  discrepancies  were 
relatively rare, i.e. in 3.6% of sera for IgG antibodies 
and 5.5% of sera for IgM antibodies. when results 
were compared between two assays (AxSYM versus 
VIDAS, and AxSYM versus VIDIA), the agreement 
was high for positive IgG results (99.6% and 99.6%, 
respectively), negative IgG results (98.8% and 99.0%, 
respectively), and negative IgM results (98.9% and 
98.7%, respectively), and was lower for positive IgM 
results (81.5% and 92.9%, respectively).  
Acute T. gondii infection in pregnant women may 
result in congenital diseases, causing abortion or severe 
damage to the fetus at birth or later in life. A specific 
and  sensitive  serological  assay  for  toxoplasmosis 
is  therefore  crucial  for  the  diagnosis  of  primary 
infection during pregnancy. To assess the specificity 
and the sensitivity of immunoassays, the choice of the 
reference method and of the tested samples must be 
considered carefully when comparing results published 
in different reports. In this study, sera were collected 
from pregnant women, and Sabin-Feldman dye test 
and ISAGA test were used to resolve discrepancies 
between AxSYM, VIDAS and VIDIA assays.
The performance of the three immunoassays was 
similar for the detection of IgG antibodies with high 
sensitivity (100.00% for VIDIA, 99.59% for VIDAS, 
99.38%  for AxSYM,)  and  specificity  (99.04%  for 
VIDIA, 98.82% for AxSYM, 98.57% for VIDAS). 
These results obtained with sera collected in Latin 
America are consistent with those reported for the 
same automated immunoassays with European sera, 
although no reference methods were used to determine 
the status of the sera.19 A slightly higher sensitivity 
of the VIDIA IgG assay versus the VIDAS IgG was 
expected, as the VIDIA assay was calibrated to be 
more sensitive with a lower threshold of positivity 
than the VIDAS assay. Specificity and sensitivity of 
automated IgG immunoassays is usually high, and 
the proportion of false positive or false negative IgG 
results is low.19,23-27 In this study, the few false negative 
IgG results obtained in VIDAS and AxSYM assays 
may be attributed to the high sensitivity of the dye test, 
which predominantly measures IgG antibodies, but also 
IgM and IgA antibodies, allowing both early and late 
diagnosis of Toxoplasma infection.13,28 False positive 
IgG results were rare in this study and corresponded 
most often to low IgG antibody titers and to different 
sera with the three immunoassays. These false results 
may be due to the different nature of the antigen used 
in the ELISA and dye tests. In the dye test, membrane 
antigens present on the surface of live T. gondii are used 
for the detection of all Ig classes.13,29 VIDAS IgG and 
AxSYM IgG assays use disrupted trophozoites (grown 
in mouse for the VIDAS assay and in vitro for AxSYM) 
exposing both membrane and cytoplasmic antigens. In 
the VIDIA IgG assay, the T. gondii antigen is produced 
in vitro, then immunopurified and corresponds mainly 
to a membrane antigen.
The specificity for the detection for IgM T. gondii 
antibodies  was  excellent  for  the  three  automated 
immunassays (99.88% for VIDIA, 99.76% for both 
AxSYM and VIDAS assays), showing only one false 
positive result for the VIDIA assay and two false 
positive results for both AxSYM and VIDAS assays. 
The specificity for the detection of T. gondii IgM 
antibodies has been questioned for some commercially 
available kits, and false positive IgM results have been 
reported.30-33 The specificity of the ELISA IgM tests 
was then improved, using the immunocapture of IgM 
antibodies. As the interpretation of the presence of IgM 
antibodies is often complex, confirmatory tests, such as 
IgA ELISA, IgE ELISA, differential agglutination test 
and IgG avidity test are strongly recommended.24,31,34,35 
The IgG avidity test is widely used, and is based on 
the principle that antibody avidity gradually increases 
after exposure to an immunogen. Low avidity of IgG 
antibodies can be used as a marker for a recent primary 
infection. In this study, most of the false positive IgM   Sci Med. 2010;20(1):27-34  33
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results  were  associated  with  low  IgM  titers.  Two 
false positive IgM results (one for AxSYM and one 
for VIDIA) were true negatives for IgG antibodies, 
suggesting that the women had not been previously 
infected. Three false positive IgM results (one for 
AxSYM and two for VIDAS) were true positives for 
IgG, and two sera tested with VIDAS displayed a 
high avidity, suggesting a past infection. In the case 
of these three sera, it cannot be ruled out that VIDAS 
and AxSYM assays detected persisting IgM antibodies. 
As for IgG antibodies, the nature of the antigens used 
in ELISA IgM and the reference test is different. 
The ISAGA test incorporates entire, formalin fixed 
trophozoites and presents mainly membrane antigens.29 
In the AxSYM, VIDAS and VIDIA IgM assays, T. 
gondii antigens are whole-cell lysates, exposing both 
membrane and cytoplasmic antigens. 
In contrast to the specificity, the sensitivity of 
the detection of IgM T. gondii antibodies differed 
between  immunoassays.  The  VIDIA  IgM  assay 
displayed a higher sensitivity (95.12%) than VIDAS 
IgM (76.74%) and AxSYM IgM (61.90%) assays. In 
some subjects IgM may persist for many months or 
even years after acute infection.36,37 Using the ISAGA 
test, IgM antibodies were shown to persist beyond 2 
years in 27.1% of sera from T. gondii-infected pregnant 
women.37 It has been reported that the ISAGA test 
can detect T. gondii IgM antibodies up to 12 years 
after primary infection, while other tests (ELISA, 
immunofluorescence, indirect hemagglutination) do 
not.36 In our study, all false negative IgM results were 
positive for IgG antibodies with the three assays. For 
13 of them, which could be tested with the VIDAS IgG 
avidity test, a high avidity was observed, suggesting 
that most of the false negative results were probably 
related to a past infection, which could still be detected 
by a highly sensitive test such as ISAGA.
Although the concordance was excellent for positive 
and negative results, the correlation between IgG titers 
was more limited between AxSYM and VIDAS assays, 
and between AxSYM and VIDIA assays. Antibody 
titers were approximately three times lower with the 
AxSYM assay, than with VIDAS and VIDIA assays. 
In contrast, antibody titers measured in VIDAS and 
VIDIA assays were very close. This may be related to 
the nature of the antigens used in the three tests, and the 
international standard used for calibration (wHO 1st for 
AxSYM, wHO 2nd for VIDAS, wHO 3rd for VIDIA). 
Anti-human IgG conjugates are also different in the 
AxSYM IgM assay (polyclonal serum) and VIDAS 
and VIDIA assays (monoclonal antibody). This inter-
technique variability in IgG antibody titer was recently 
reported. Various sera were tested in six IgG automated 
immunoassays. The median of the results varied by a 
factor of 1 to 25 depending on the test used.27 According 
to AFSSAPS (Agence Francaise de Sécurité Sanitaire 
des Produits de Santé) recommendations,38 antibody 
titers or paired sera should only be compared using 
the same test.
In conclusion, our study performed with Latin 
American sera confirmed the excellent specificity of 
AxSYM, VIDAS and VIDIA assays for the detection 
of IgG and IgM T. gondii antibodies already reported 
in other countries. The sensitivity of the detection of 
IgG antibodies was slightly higher with VIDIA than 
with VIDAS and AxSYM assays. The sensitivity of the 
detection of IgM antibodies was higher with VIDIA 
than with VIDAS and AxSYM assays.
The determination of the immune status of pregnant 
women is essential for defining the appropriate follow-
up and prophylactic measures. Therefore, positive 
or  equivocal  IgM  results  should  be  followed  by 
confirmatory testing at a reference laboratory, and 
interpreted in association with IgG results and other 
tests, such as the IgG avidity test.35
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